Compare Summit Therapeutics Inc (SMMT) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Tenet Healthcare Corporation — how do they compare? Summit Therapeutics Inc trades at $15.1 (market cap $12.06B), while Tenet Healthcare Corporation trades at $267.21 (market cap $20.89B). The key difference: Tenet Healthcare Corporation is the larger of the two by market cap, and Tenet Healthcare Corporation is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMMT | THC | |
|---|---|---|
Market Cap | $12.06B | $20.89B |
Sector | Health | Health |
52-Week High | $26.98 | $262.63 |
52-Week Low | $12.55 | $161.37 |
Enterprise Value | $11.39B | $31.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Tenet Healthcare (THC) trades at $266.15, up 2.39% today, with strong technical momentum including a golden cross formation. The stock shows robust fundamentals with a P/E of 10.03, net income margin of 9.9%, and consistent earnings beats in recent quarters. Recent Q2 2026 results exceeded expectations with EPS of $6.12 versus $4.26 estimate, driving positive analyst sentiment.
Outlook remains positive with 81% analyst buy ratings and $281.44 consensus price target, though investors should monitor policy headwinds in healthcare and the stock's proximity to 52-week highs. The company's ambulatory growth and raised 2026 guidance support continued upside potential despite net cash flow challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
